Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Li‐Tzong Chen(Kaohsiung Medical University), Étienne Dorval(Centre Hospitalier Universitaire de Tours), Masatoshi Kudo(Kindai University), Eric Assénat, Kevin Perraud(Novartis (Switzerland)), Junji Furuse(Kanagawa Prefectural Hospital Organization), Bruno Daniele(Azienda Ospedaliera G.Rummo), Dalila Sellami(Daiichi Sankyo (United States)), Annette Jappe(Novartis (Switzerland)), Markus Peck‐Radosavljevic(Klinikum Klagenfurt), Arndt Vogel(Princess Margaret Cancer Centre), Oezlem Anak(Novartis (Switzerland)), Armando Santoro(IRCCS Humanitas Research Hospital), Jean-Frédéric Blanc(Hôpital Saint-André), Stéphane Cattan(Université Lille Nord de France), Ronnie T.P. Poon(University of Hong Kong), Yoon‐Koo Kang(Ulsan College), Chao‐Long Chen(Memorial Hospital of South Bend), Ho Yeong Lim(CHA University Bundang Medical Center)
Cited by 569
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k